Molecular Analysis and Treatment Options of Thymic Malignancies

Recruiting now

Conditions studied: Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer

In brief

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Key facts

Study ID

NCT05667948

Run by

Shanghai Chest Hospital

People needed

500

Starts

2016-01-01

Expected to finish

2026-12-31

Last updated by the study team

2025-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven diagnosis of thymic malignancies
• 18 years of age or older
• Ability to understand and the willingness to sign a written informed consent document

Where it is running

• Xiaomin Niu — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.